RCOR.WS / Renovacor, Inc. Warrants, enti Warrants, entitling the holder thereof to purchase one-half (1/2) of a share of common stock at a price of $11.50 per whole share - Pengajuan SECLaporan Tahunan, Pernyataan Proksi

CHAQ / Chardan Healthcare Acquisition 2 Corp / RTW INVESTMENTS, LP - RENOVACOR, INC. Activist Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) Under the Securities Exchange Act of 1934 (Amendment No. 1) Renovacor, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 75989E106 (CUSIP Number) Eleazer

CHAQ / Chardan Healthcare Acquisition 2 Corp / CITADEL ADVISORS LLC - SC 13G/A Passive Investment

SC 13G/A 1 tm233066-24sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 (Amendment No. 2)* RENOVACOR, INC. (Name of Issuer) Common Stock, par value $0.0001 per share (the “Shares”) (Title

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number 001-39271 Renovacor, Inc. (ZEBRAFISH MERGER SUB II, LLC, AS SUCCESSOR TO REN

As filed with the Securities and Exchange Commission on December 1, 2022.

As filed with the Securities and Exchange Commission on December 1, 2022. Registration No. 333-236977 Registration No. 333-260299 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO Form S-1 Registration No. 333-236977 Form S-1 Registration No. 333-260299 UNDER THE SECURITIES ACT OF 1933 Renovacor, Inc. (ZEBRAFISH MERGER SUB II, LLC, AS SUCCESS

Certificate of Formation of Zebrafish Merger Sub II, LLC.

Exhibit 3.1 CERTIFICATE OF FORMATION OF ZEBRAFISH E MERGER SUB II, LLC This Certificate of Formation of Zebrafish Merger Sub II, LLC, is being duly executed and filed by the undersigned, to form a limited liability company under the Delaware Limited Liability Company Act (6 Del.C ?18-101, et seq.). FIRST: The name of the limited liability company is Zebrafish Merger Sub II, LLC (the ?Company?). SE

As filed with the Securities and Exchange Commission on December 1, 2022

As filed with the Securities and Exchange Commission on December 1, 2022 Registration No.

EX-99.25

NOTIFICATION OF THE REMOVAL FROM LISTING AND REGISTRATION OF THE STATED SECURITIES NYSE American LLC hereby notifies the SEC of its intention to remove the entire class of the stated securities from listing and registration on the Exchange at the opening of business on December 12, 2022, pursuant to the provisions of Rule 12d2-2 (a).

As filed with the Securities and Exchange Commission on December 1, 2022.

As filed with the Securities and Exchange Commission on December 1, 2022. Registration No. 333-236977 Registration No. 333-260299 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO Form S-1 Registration No. 333-236977 Form S-1 Registration No. 333-260299 UNDER THE SECURITIES ACT OF 1933 Renovacor, Inc. (ZEBRAFISH MERGER SUB II, LLC, AS SUCCESS

Limited Liability Company Agreement of Zebrafish Merger Sub II, LLC.

Exhibit 3.2 ZEBRAFISH MERGER SUB II, LLC a Delaware limited liability company LIMITED LIABILITY COMPANY OPERATING AGREEMENT September 16, 2022 LIMITED LIABILITY COMPANY OPERATING AGREEMENT This LIMITED LIABILITY COMPANY OPERATING AGREEMENT, dated as of September 16, 2022 (this ?Agreement?), of Zebrafish Merger Sub II, LLC, a Delaware limited liability company (the ?Company?), is entered into betwe

Changes in Control of Registrant, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Material Modification to Rights of Security Holders, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 30, 2022 RENOVACOR, INC. (ZEBRAFISH MERGER SUB II, LLC, AS SUCCESSOR TO RENOVACOR, INC.) (Exact name of registrant as specified in its charter) Delaware 001-39271 83-3169838

As filed with the Securities and Exchange Commission on December 1, 2022

As filed with the Securities and Exchange Commission on December 1, 2022 Registration No.

UP TO 8,526,546 SHARES OF COMMON STOCK ISSUABLE UPON THE EXERCISE OF WARRANTS UP TO 12,668,314 SHARES OF COMMON STOCK UP TO 3,500,000 PRIVATE PLACEMENT WARRANTS

424B3 1 rcor424b3-20220930-10q.htm 424B3 Filed Pursuant to Rule 424(b)(3) Registration No. 333-260299 Prospectus Supplement No. 13 (to prospectus dated November 1, 2021) UP TO 8,526,546 SHARES OF COMMON STOCK ISSUABLE UPON THE EXERCISE OF WARRANTS UP TO 12,668,314 SHARES OF COMMON STOCK UP TO 3,500,000 PRIVATE PLACEMENT WARRANTS This prospectus supplement (this “Prospectus Supplement”) is being fi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39271 Renovacor, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a party other than the Registrant ?? Check the appropriate box: ?? ? ? Preliminary Proxy Statement ?? ? ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 14, 2022 Renovacor, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39271 83-3169838 (State or Other Jurisdiction of Incorporation) (Commission File N

Forward Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this communication that do not relate to matters of historical fa

Exhibit 99.1 RENOVACOR CORPORATE PRESENTATION NYSE: RCOR October 2022 Forward Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this communication that do not relate to matters of historical fact should be considered forward-looking statements, including statements regardi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 14, 2022 Renovacor, Inc.

425 1 d370300d425.htm 425 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 14, 2022 Renovacor, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39271 83-3169838 (State or Other Jurisdiction of Incorpo

Filed by Renovacor, Inc.

Filed by Renovacor, Inc. pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: Renovacor, Inc. Commission File No.: 001-39271 Date: September 23, 2022 Renovacor Employee ?Frequently Asked Questions? Document ? September 23, 2022 1. What was announced? On September 20, 2022, we announced the signing

Filed by Renovacor, Inc.

Filed by Renovacor, Inc. pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: Renovacor, Inc. Commission File No.: 001-39271 Date: September 23, 2022 Dear Renovacor Team, Per the announcement earlier this week, I am excited to share the news with you that we have signed a definitive agreement with

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 22, 2022 Renovacor, Inc

425 1 d371007d425.htm 425 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 22, 2022 Renovacor, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39271 83-3169838 (State or Other Jurisdiction of Incor

Forward Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this communication that do not relate to matters of historical fa

RENOVACOR CORPORATE PRESENTATION NYSE: RCOR September 2022 Exhibit 99.1 Forward Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this communication that do not relate to matters of historical fact should be considered forward-looking statements, including statements regar

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 22, 2022 Renovacor, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39271 83-3169838 (State or Other Jurisdiction of Incorporation) (Commission File

UP TO 8,526,546 SHARES OF COMMON STOCK ISSUABLE UPON THE EXERCISE OF WARRANTS UP TO 12,668,314 SHARES OF COMMON STOCK UP TO 3,500,000 PRIVATE PLACEMENT WARRANTS

424B3 1 d388726d424b3.htm 424B3 Filed Pursuant to Rule 424(b)(3) Registration No. 333-260299 Prospectus Supplement No. 12 (to prospectus dated November 1, 2021) UP TO 8,526,546 SHARES OF COMMON STOCK ISSUABLE UPON THE EXERCISE OF WARRANTS UP TO 12,668,314 SHARES OF COMMON STOCK UP TO 3,500,000 PRIVATE PLACEMENT WARRANTS This prospectus supplement (this “Prospectus Supplement”) is being filed to up

CHAQ / Chardan Healthcare Acquisition 2 Corp / RTW INVESTMENTS, LP - RENOVACOR, INC. Activist Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) Under the Securities Exchange Act of 1934 (Amendment No. ) Renovacor, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 75989E106 (CUSIP Number) Eleazer Kle

VOTING AGREEMENT

Exhibit 99.1 Execution Version VOTING AGREEMENT THIS VOTING AGREEMENT (this ?Agreement?) is made and entered into as of September , 2022, by and between Renovacor, Inc., a Delaware corporation (the ?Company?) and the undersigned stockholder (the ?Stockholder?) of Rocket Pharmaceuticals, Inc., a Delaware corporation (?Parent?). WITNESSETH: WHEREAS, contemporaneously with the execution of this Agree

VOTING AGREEMENT

Exhibit 99.2 Execution Version VOTING AGREEMENT THIS VOTING AGREEMENT (this ?Agreement?) is made and entered into as of September , 2022, by and between Rocket Pharmaceuticals, Inc., a Delaware corporation (?Parent?), and the undersigned stockholder (the ?Stockholder?) of Renovacor, Inc., a Delaware corporation (the ?Company?). WITNESSETH: WHEREAS, contemporaneously with the execution of this Agre

Rocket Pharmaceuticals to Acquire Renovacor, Extending Leadership in AAV-based Cardiac Gene Therapy • Acquisition further strengthens Rocket’s leadership in AAV-based cardiac gene therapy and expands Company’s near-term clinical assets for the treatm

Exhibit 99.3 Rocket Pharmaceuticals to Acquire Renovacor, Extending Leadership in AAV-based Cardiac Gene Therapy ? Acquisition further strengthens Rocket?s leadership in AAV-based cardiac gene therapy and expands Company?s near-term clinical assets for the treatment of heart conditions ? Significant unmet medical need in BAG3-associated dilated cardiomyopathy, with meaningful commercial opportunit

AGREEMENT AND PLAN OF MERGER by and among ROCKET PHARMACEUTICALS, INC., ZEBRAFISH MERGER SUB, INC., ZEBRAFISH MERGER SUB II, LLC, RENOVACOR, INC. dated as of September 19, 2022 TABLE OF CONTENTS

Exhibit 2.1 Execution Version AGREEMENT AND PLAN OF MERGER by and among ROCKET PHARMACEUTICALS, INC., ZEBRAFISH MERGER SUB, INC., ZEBRAFISH MERGER SUB II, LLC, and RENOVACOR, INC. dated as of September 19, 2022 TABLE OF CONTENTS Page ARTICLE I DEFINITIONS 2 Section 1.01. Certain Definitions 2 Section 1.02. Other Definitional Provisions 21 ARTICLE II THE MERGERS 22 Section 2.01. The Mergers 22 Sect

Company Name: Rocket Pharmaceuticals Inc Company Ticker: RCKT US Equity Date: 2022-09-20 Acquisition of Renovacor, Inc by Rocket Pharmaceuticals, Inc Company Participants Gaurav Shah, CEO Jessie Yeung, VP of Investor Relations and Corporate Finance O

Filed by Rocket Pharmaceuticals, Inc. pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: Renovacor, Inc. Commission File No.: 001-39271 Date: September 20, 2022 This filing relates to the proposed acquisition of Renovacor, Inc., a Delaware corporation (the ?Company?), by Rocket Pharmaceuticals, I

INVESTOR DECK INVESTOR DECK INVESTOR DECK ROCKET PHARMA ACQUISITION OF RENOVACOR September 20, 2022 DISCLAIMER Various statements in this release concerning Rocket's future expectations, plans and prospects, including without limitation, Rocket's exp

425 1 brhc10042075425.htm 425 Filed by Rocket Pharmaceuticals, Inc. pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: Renovacor, Inc. Commission File No.: 001-39271 Date: September 20, 2022 This filing relates to the proposed acquisition of Renovacor, Inc., a Delaware corporation (the “Company”)

Rocket Pharmaceuticals to Acquire Renovacor, Extending Leadership in AAV-based Cardiac Gene Therapy • Acquisition further strengthens Rocket’s leadership in AAV-based cardiac gene therapy and expands Company’s near-term clinical assets for the treatm

Exhibit 99.3 Rocket Pharmaceuticals to Acquire Renovacor, Extending Leadership in AAV-based Cardiac Gene Therapy ? Acquisition further strengthens Rocket?s leadership in AAV-based cardiac gene therapy and expands Company?s near-term clinical assets for the treatment of heart conditions ? Significant unmet medical need in BAG3-associated dilated cardiomyopathy, with meaningful commercial opportunit

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 19, 2022 Renovacor, Inc

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 19, 2022 Renovacor, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39271 83-3169838 (State or Other Jurisdiction of Incorporation) (Commission File

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 19, 2022 Renovacor, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39271 83-3169838 (State or Other Jurisdiction of Incorporation) (Commission File

VOTING AGREEMENT

Exhibit 99.2 Execution Version VOTING AGREEMENT THIS VOTING AGREEMENT (this ?Agreement?) is made and entered into as of September , 2022, by and between Rocket Pharmaceuticals, Inc., a Delaware corporation (?Parent?), and the undersigned stockholder (the ?Stockholder?) of Renovacor, Inc., a Delaware corporation (the ?Company?). WITNESSETH: WHEREAS, contemporaneously with the execution of this Agre

Agreement and Plan of Merger, dated as of September 19, 2022, by and among Renovacor, Inc, Rocket Pharmaceuticals, Inc., Merger Sub I and Merger Sub II.

Exhibit 2.1 Execution Version AGREEMENT AND PLAN OF MERGER by and among ROCKET PHARMACEUTICALS, INC., ZEBRAFISH MERGER SUB, INC., ZEBRAFISH MERGER SUB II, LLC, and RENOVACOR, INC. dated as of September 19, 2022 TABLE OF CONTENTS Page ARTICLE I DEFINITIONS 2 Section 1.01. Certain Definitions 2 Section 1.02. Other Definitional Provisions 17 ARTICLE II THE MERGERS 18 Section 2.01. The Mergers 18 Sect

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 19, 2022 Rocket Pharmaceu

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 19, 2022 Rocket Pharmaceuticals, Inc.

VOTING AGREEMENT

Exhibit 99.1 Execution Version VOTING AGREEMENT THIS VOTING AGREEMENT (this ?Agreement?) is made and entered into as of September , 2022, by and between Renovacor, Inc., a Delaware corporation (the ?Company?) and the undersigned stockholder (the ?Stockholder?) of Rocket Pharmaceuticals, Inc., a Delaware corporation (?Parent?). WITNESSETH: WHEREAS, contemporaneously with the execution of this Agree

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39271 Renovacor, Inc.

REN-001 IND submission planned for the second half of 2022 Data from pilot pig study showing successful cardiac transduction with REN-001 delivered via low-dose retrograde coronary sinus infusion published in Journal of the American College of Cardio

Exhibit 99.1 Renovacor Reports Second Quarter 2022 Financial Results and Provides Corporate Update REN-001 IND submission planned for the second half of 2022 Data from pilot pig study showing successful cardiac transduction with REN-001 delivered via low-dose retrograde coronary sinus infusion published in Journal of the American College of Cardiology: Basic to Translational Science Cambridge, Mas

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2022 Renovacor, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39271 83-3169838 (State or Other Jurisdiction of Incorporation) (Commission File Num

UP TO 8,526,546 SHARES OF COMMON STOCK ISSUABLE UPON THE EXERCISE OF WARRANTS UP TO 12,668,314 SHARES OF COMMON STOCK UP TO 3,500,000 PRIVATE PLACEMENT WARRANTS

424B3 1 rcor424b3-20220630-10q.htm 424B3 Filed Pursuant to Rule 424(b)(3) Registration No. 333-260299 Prospectus Supplement No. 11 (to prospectus dated November 1, 2021) UP TO 8,526,546 SHARES OF COMMON STOCK ISSUABLE UPON THE EXERCISE OF WARRANTS UP TO 12,668,314 SHARES OF COMMON STOCK UP TO 3,500,000 PRIVATE PLACEMENT WARRANTS This prospectus supplement (this “Prospectus Supplement”) is being fi

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 12, 2022 Renovacor, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39271 83-3169838 (State or Other Jurisdiction of Incorporation) (Commission File Numb

Forward Looking Statements Certain statements in this Presentation may be considered forward-looking statements within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995, as amended. Forw

RENOVACOR CORPORATE PRESENTATION NYSE: RCOR July 2022 Exhibit 99.1 Forward Looking Statements Certain statements in this Presentation may be considered forward-looking statements within the meaning of the ?safe harbor? provisions of the United States Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements generally relate to future events or the Company?s future ?n

Employment Agreement, by and between the Company and Joseph Carroll, dated as of June 17, 2022 (incorporated by reference to Exhibit 10.2 of the Registrant’s Current Report on Form 8-K/A, filed with the Securities & Exchange Commission on June 24, 2022).

Exhibit 10.2 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (this ?Agreement?) is made, entered into by and between Renovacor, Inc., a Delaware corporation (the ?Company?), and Joe Carroll (the ?Executive?), dated June 17, 2022 (the ?Effective Date?). WHEREAS, the Executive possesses certain experience and expertise that qualifies him to provide the direction and leadership required by the Company

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A Amendment No. 1 CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 30, 2022 Renovacor, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39271 83-3169838 (State or Other Jurisdiction of Incorporation) (Com

UP TO 8,526,546 SHARES OF COMMON STOCK ISSUABLE UPON THE EXERCISE OF WARRANTS UP TO 12,668,314 SHARES OF COMMON STOCK UP TO 3,500,000 PRIVATE PLACEMENT WARRANTS

Filed Pursuant to Rule 424(b)(3) Registration No. 333-260299 Prospectus Supplement No. 10 (to prospectus dated November 1, 2021) UP TO 8,526,546 SHARES OF COMMON STOCK ISSUABLE UPON THE EXERCISE OF WARRANTS UP TO 12,668,314 SHARES OF COMMON STOCK UP TO 3,500,000 PRIVATE PLACEMENT WARRANTS This prospectus supplement (this ?Prospectus Supplement?) is being filed to update and supplement the informat

CFO Services Agreement, by and between the Company and Wendy DiCicco, dated as of June 17, 2022 (incorporated by reference to Exhibit 10.1 of the Registrant’s Current Report on Form 8-K/A, filed with the Securities & Exchange Commission on June 24, 2022).

Exhibit 10.1 CFO SERVICES AGREEMENT This CFO SERVICES AGREEMENT (this ?Agreement?) is made, entered into by and between Renovacor, Inc., a Delaware corporation (the ?Company?), and Wendy F. DiCicco (the ?Officer?), dated June 17, 2022 (the ?Effective Date?). WHEREAS, the Officer possesses certain experience and expertise that qualifies the Officer to serve as the Company?s principal financial offi

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 30, 2022 Renovacor, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39271 83-3169838 (State or Other Jurisdiction of Incorporation) (Commission File Numbe

UP TO 8,526,546 SHARES OF COMMON STOCK ISSUABLE UPON THE EXERCISE OF WARRANTS UP TO 12,668,314 SHARES OF COMMON STOCK UP TO 3,500,000 PRIVATE PLACEMENT WARRANTS

Filed Pursuant to Rule 424(b)(3) Registration No. 333-260299 Prospectus Supplement No. 9 (to prospectus dated November 1, 2021) UP TO 8,526,546 SHARES OF COMMON STOCK ISSUABLE UPON THE EXERCISE OF WARRANTS UP TO 12,668,314 SHARES OF COMMON STOCK UP TO 3,500,000 PRIVATE PLACEMENT WARRANTS This prospectus supplement (this ?Prospectus Supplement?) is being filed to update and supplement the informati

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 1, 2022 Renovacor, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39271 83-3169838 (State or Other Jurisdiction of Incorporation) (Commission File Numbe

UP TO 8,526,546 SHARES OF COMMON STOCK ISSUABLE UPON THE EXERCISE OF WARRANTS UP TO 12,668,314 SHARES OF COMMON STOCK UP TO 3,500,000 PRIVATE PLACEMENT WARRANTS

Filed Pursuant to Rule 424(b)(3) Registration No. 333-260299 Prospectus Supplement No. 8 (to prospectus dated November 1, 2021) UP TO 8,526,546 SHARES OF COMMON STOCK ISSUABLE UPON THE EXERCISE OF WARRANTS UP TO 12,668,314 SHARES OF COMMON STOCK UP TO 3,500,000 PRIVATE PLACEMENT WARRANTS This prospectus supplement (this ?Prospectus Supplement?) is being filed to update and supplement the informati

Forward Looking Statements Certain statements in this Presentation may be considered forward-looking statements within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995, as amended. Forw

EX-99.1 RENOVACOR CORPORATE PRESENTATION NYSE: RCOR June 2022 Exhibit 99.1 Forward Looking Statements Certain statements in this Presentation may be considered forward-looking statements within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements generally relate to future events or the Company’s f

UP TO 8,526,546 SHARES OF COMMON STOCK ISSUABLE UPON THE EXERCISE OF WARRANTS UP TO 12,668,314 SHARES OF COMMON STOCK UP TO 3,500,000 PRIVATE PLACEMENT WARRANTS

Filed Pursuant to Rule 424(b)(3) Registration No. 333-260299 Prospectus Supplement No. 7 (to prospectus dated November 1, 2021) UP TO 8,526,546 SHARES OF COMMON STOCK ISSUABLE UPON THE EXERCISE OF WARRANTS UP TO 12,668,314 SHARES OF COMMON STOCK UP TO 3,500,000 PRIVATE PLACEMENT WARRANTS This prospectus supplement (this ?Prospectus Supplement?) is being filed to update and supplement the informati

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 25, 2022 Renovacor, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39271 83-3169838 (State or Other Jurisdiction of Incorporation) (Commission File Numbe

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2022 Renovacor, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39271 83-3169838 (State or Other Jurisdiction of Incorporation) (Commission File Numbe

REN-001 advancing toward IND submission in the second half of 2022 with the initiation of a Phase I/II clinical trial in BAG3-DCM expected thereafter Strengthened executive team with appointment of Fred Driscoll as CFO

Exhibit 99.1 Renovacor Reports First Quarter 2022 Financial Results and Provides Corporate Update REN-001 advancing toward IND submission in the second half of 2022 with the initiation of a Phase I/II clinical trial in BAG3-DCM expected thereafter Strengthened executive team with appointment of Fred Driscoll as CFO CAMBRIDGE, Mass. ? May 12, 2022 ? Renovacor, Inc. (NYSE: RCOR), a biotechnology com

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39271 Renovacor, Inc.

UP TO 8,526,546 SHARES OF COMMON STOCK ISSUABLE UPON THE EXERCISE OF WARRANTS UP TO 12,668,314 SHARES OF COMMON STOCK UP TO 3,500,000 PRIVATE PLACEMENT WARRANTS

Filed Pursuant to Rule 424(b)(3) Registration No. 333-260299 Prospectus Supplement No. 6 (to prospectus dated November 1, 2021) UP TO 8,526,546 SHARES OF COMMON STOCK ISSUABLE UPON THE EXERCISE OF WARRANTS UP TO 12,668,314 SHARES OF COMMON STOCK UP TO 3,500,000 PRIVATE PLACEMENT WARRANTS This prospectus supplement (this ?Prospectus Supplement?) is being filed to update and supplement the informati

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin

UP TO 8,526,546 SHARES OF COMMON STOCK ISSUABLE UPON THE EXERCISE OF WARRANTS UP TO 12,668,314 SHARES OF COMMON STOCK UP TO 3,500,000 PRIVATE PLACEMENT WARRANTS

Filed Pursuant to Rule 424(b)(3) Registration No. 333-260299 Prospectus Supplement No. 5 (to prospectus dated November 1, 2021) UP TO 8,526,546 SHARES OF COMMON STOCK ISSUABLE UPON THE EXERCISE OF WARRANTS UP TO 12,668,314 SHARES OF COMMON STOCK UP TO 3,500,000 PRIVATE PLACEMENT WARRANTS This prospectus supplement (this ?Prospectus Supplement?) is being filed to update and supplement the informati

Employment Agreement, by and between the Company and Frederick Driscoll, dated as of March 3, 2022 and effective as of March 28, 2022 (incorporated by reference to Exhibit 10.1 of the Registrant’s Current Report on Form 8-K, filed with the Securities & Exchange Commission on March 28, 2022).

Exhibit 10.1 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (this ?Agreement?) is made, entered into by and between Renovacor, Inc., a Delaware corporation (the ?Company?), and Fred Driscoll (the ?Executive?), dated March 3, 2022. WHEREAS, the Executive possesses certain experience and expertise that qualifies him to provide the direction and leadership required by the Company; WHEREAS, the Compan

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 28, 2022 Renovacor, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-39271 83-3169838 (State or Other Jurisdiction of Incorporation) (Commission File Number)

Form of Earnout Restricted Stock Award Under the 2021 Omnibus Incentive Plan.

Exhibit 10.11 NOTICE OF GRANT OF RESTRICTED STOCK UNITS AWARD (Earnout RSUs) RENOVACOR, INC. 2021 OMNIBUS INCENTIVE PLAN Renovacor, Inc. (the ?Company?) hereby grants this award of a Restricted Stock Units (the ?Units?) as set forth in this Notice of Grant of Restricted Stock Units Award (the ?Notice?) to the Grantee designated in this Notice, pursuant to the provisions of the Company?s 2021 Omnib

Debuted as a public company and raised gross proceeds of $95.1 million from the business combination with Chardan Healthcare Acquisition 2 Corp and a concurrent PIPE financing Strengthened company leadership with key appointments including Marc Semig

Exhibit 99.1 Renovacor Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update Debuted as a public company and raised gross proceeds of $95.1 million from the business combination with Chardan Healthcare Acquisition 2 Corp and a concurrent PIPE financing Strengthened company leadership with key appointments including Marc Semigran, M.D., as CMO, Matthew Killeen, P

As filed with the Securities and Exchange Commission on March 24, 2022

As filed with the Securities and Exchange Commission on March 24, 2022 Registration No.

UP TO 8,526,546 SHARES OF COMMON STOCK ISSUABLE UPON THE EXERCISE OF WARRANTS UP TO 12,668,314 SHARES OF COMMON STOCK UP TO 3,500,000 PRIVATE PLACEMENT WARRANTS

Filed Pursuant to Rule 424(b)(3) Registration No. 333-260299 Prospectus Supplement No. 4 (to prospectus dated November 1, 2021) UP TO 8,526,546 SHARES OF COMMON STOCK ISSUABLE UPON THE EXERCISE OF WARRANTS UP TO 12,668,314 SHARES OF COMMON STOCK UP TO 3,500,000 PRIVATE PLACEMENT WARRANTS This prospectus supplement (this ?Prospectus Supplement?) is being filed to update and supplement the informati

RENOVACOR CORPORATE PRESENTATION NYSE: RCOR March 2022

RENOVACOR CORPORATE PRESENTATION NYSE: RCOR March 2022 Forward Looking Statements Certain statements in this Presentation may be considered forward-looking statements within the meaning of the ?safe harbor? provisions of the United States Private Securities Litigation Reform Act of 1995, as amended.

Filing Fee Table.

Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Renovacor, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1)(2) Proposed Maximum Offering Price Per Unit(3) Maximum Aggregate Offering Price(3) Fee Rate Amount of Registration Fee Equity Common Stock, par value

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 24, 2022 Renovacor, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39271 83-3169838 (State or Other Jurisdiction of Incorporation) (Commission File Num

Description of the Renovacor, Inc. Securities Registered Under Section 12 of the Securities Exchange Act of 1934.

Exhibit 4.5 DESCRIPTION OF THE REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following descriptions are summaries of the material terms of our second amended and restated certificate of incorporation, amended and restated bylaws, our Public Warrants (as defined below) and of the Delaware General Corporation Law (the ?DGCL?). Because the follow

List of Subsidiaries.

Exhibit 21.1 SUBSIDIARIES OF THE REGISTRANT Name of Subsidiary Name(s) Under Which the Subsidiary Does Business Jurisdiction of Incorporation Renovacor Holdings, Inc.* Renovacor, Renovacor, Inc. USA (Delaware) * Wholly-owned subsidiary of the Registrant.

Form of Restricted Stock Award Under the 2021 Omnibus Incentive Plan.

Exhibit 10.12 NOTICE OF GRANT OF RESTRICTED STOCK UNITS AWARD (Time-vesting) RENOVACOR, INC. 2021 OMNIBUS INCENTIVE PLAN Renovacor, Inc. (the ?Company?) hereby grants this award of a Restricted Stock Units (the ?Units?) as set forth in this Notice of Grant of Restricted Stock Units Award (the ?Notice?) to the Grantee designated in this Notice, pursuant to the provisions of the Company?s 2021 Omnib

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39271 Renovacor, Inc.

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 2, 2022 Renovacor, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39271 83-3169838 (State or Other Jurisdiction of Incorporation) (Commission File Numb

RENOVACOR CORPORATE PRESENTATION NYSE: RCOR March 2022

RENOVACOR CORPORATE PRESENTATION NYSE: RCOR March 2022 Forward Looking Statements Certain statements in this Presentation may be considered forward-looking statements within the meaning of the ?safe harbor? provisions of the United States Private Securities Litigation Reform Act of 1995, as amended.

UP TO 8,526,546 SHARES OF COMMON STOCK ISSUABLE UPON THE EXERCISE OF WARRANTS UP TO 12,668,314 SHARES OF COMMON STOCK UP TO 3,500,000 PRIVATE PLACEMENT WARRANTS

Filed Pursuant to Rule 424(b)(3) Registration No. 333-260299 Prospectus Supplement No. 3 (to prospectus dated November 1, 2021) UP TO 8,526,546 SHARES OF COMMON STOCK ISSUABLE UPON THE EXERCISE OF WARRANTS UP TO 12,668,314 SHARES OF COMMON STOCK UP TO 3,500,000 PRIVATE PLACEMENT WARRANTS This prospectus supplement (this ?Prospectus Supplement?) is being filed to update and supplement the informati

CHAQ / Chardan Healthcare Acquisition 2 Corp / CITADEL ADVISORS LLC - RENOVACOR, INC. Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO ? 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO ? 240.13d-2 (Amendment No. 1)* Renovacor, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (the ?Shares?) (Title of Class of Securities) 75989E106 (CUSIP N

CHAQ / Chardan Healthcare Acquisition 2 Corp / Altium Capital Management LP - SCHEDULE FILED TO REPORT ACQUISITION OF BENEFICIAL OWNERSHIP Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Renovacor, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 75989E106 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule

CHAQ / Chardan Healthcare Acquisition 2 Corp / RTW INVESTMENTS, LP - RENOVACOR, INC. Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Renovacor, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 75989E106 (CUSIP Number) December 31, 2021 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursuant to w

EXHIBIT 1

EX-1 2 ex-1.htm JOINT ACQUISITION STATEMENT Renovacor, Inc. SC 13G EXHIBIT 1 JOINT ACQUISITION STATEMENT PURSUANT TO SECTION 240.13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the

CHAQ / Chardan Healthcare Acquisition 2 Corp / PERISCOPE CAPITAL INC. - SCHEDULE 13G/A Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Renovacor Inc (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 75989E106 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pur

CHAQ / Chardan Healthcare Acquisition 2 Corp / Oliveira Steven Michael - SC 13G/A Passive Investment

SC 13G/A 1 tm223894d1sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Amendment No. 1)* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO §240.13d-2 Renovacor, Inc. f/k/a Chardan Healthcare Acquisition 2 Corp. (Name of Issuer) Common Stock, $0.0001 p

CHAQ / Chardan Healthcare Acquisition 2 Corp / K2 PRINCIPAL FUND, L.P. Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G/A (Rule 13d-102) Amendment No. 1 Under the Securities Exchange Act of 1934 Renovacor fka Chardan Healthcare Acquisition 2 Corp. (Name of Issuer) Common Shares (Title of Class of Securities) 75989E106 (CUSIP Number) September 02, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box

Renovacor, Inc. Consolidated Statements of Operations (In thousands, except share and per share data)

Exhibit 99.1 Renovacor Announces Third Quarter 2021 Financial Results and Provides Corporate Update Debuted as a public company and strengthened liquidity position with $95.1 million in gross proceeds from the business combination with Chardan Healthcare Acquisition 2 Corp and concurrent PIPE financing Released topline preclinical data demonstrating feasibility of REN-001 to transduce a large anim

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39271 Renovacor, Inc.

UP TO 8,526,546 SHARES OF COMMON STOCK ISSUABLE UPON THE EXERCISE OF WARRANTS UP TO 12,668,314 SHARES OF COMMON STOCK UP TO 3,500,000 PRIVATE PLACEMENT WARRANTS

Filed Pursuant to Rule 424(b)(3) Registration No. 333-260299 Prospectus Supplement No. 2 (to prospectus dated November 1, 2021) UP TO 8,526,546 SHARES OF COMMON STOCK ISSUABLE UPON THE EXERCISE OF WARRANTS UP TO 12,668,314 SHARES OF COMMON STOCK UP TO 3,500,000 PRIVATE PLACEMENT WARRANTS This prospectus supplement (this ?Prospectus Supplement?) updates and supplements the information contained in

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 15, 2021 Renovacor, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39271 83-3169838 (State or Other Jurisdiction of Incorporation) (Commission File

Renovacor, Inc. 2018 Stock Option and Grant Plan (incorporated by reference to Exhibit 99.2 of the Company's Form S-8, filed with the SEC on November 12, 2021).

Exhibit 99.2 RENOVACOR, INC. 2018 STOCK OPTION AND GRANT PLAN Section 1. GENERAL PURPOSE OF THE PLAN, DEFINITIONS The name of the plan is the Renovacor, Inc. 2018 Stock Option and Grant Plan (the “Plan”). The purpose of the Plan is to encourage and enable the officers, employees or directors of, and consultants (whether individuals or entities) to, Renovacor, Inc. (including any successor entity,

Amendment 2019-1 to Renovacor, Inc. 2018 Stock Option and Grant Plan, dated as of August 12, 2019 (incorporated by reference to Exhibit 99.2 of the Company's Form S-8, filed with the SEC on November 12, 2021).

Exhibit 99.3 RENOVACOR, INC. AMENDMENT 2019-1 TO RENOVACOR, INC. 2018 STOCK OPTION AND GRANT PLAN WHEREAS, Renovacor, Inc. (the ?Company?) maintains the Renovacor, Inc. 2018 Stock Option and Grant Plan (the ?Plan?); WHEREAS, the Board of Directors and the stockholders of the Company have approved the amendment of the Plan as set forth herein. NOW, THEREFORE, in accordance with the foregoing, effec

As filed with the Securities and Exchange Commission on November 12, 2021

As filed with the Securities and Exchange Commission on November 12, 2021 File No.

UP TO 8,526,546 SHARES OF COMMON STOCK ISSUABLE UPON THE EXERCISE OF WARRANTS UP TO 12,668,314 SHARES OF COMMON STOCK UP TO 3,500,000 PRIVATE PLACEMENT WARRANTS

Filed Pursuant to Rule 424(b)(3) Registration No. 333-260299 Prospectus Supplement No. 1 (to prospectus dated November 1, 2021) UP TO 8,526,546 SHARES OF COMMON STOCK ISSUABLE UPON THE EXERCISE OF WARRANTS UP TO 12,668,314 SHARES OF COMMON STOCK UP TO 3,500,000 PRIVATE PLACEMENT WARRANTS This prospectus supplement (this ?Prospectus Supplement?) is being filed to update and supplement the informati

Forward Looking Statements Certain statements in this Presentation may be considered forward-looking statements within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995, as amended. Forw

RENOVACOR COPORATE PRESENTATION NYSE: RCOR November 2021 Exhibit 99.1 Forward Looking Statements Certain statements in this Presentation may be considered forward-looking statements within the meaning of the ?safe harbor? provisions of the United States Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements generally relate to future events or the Company?s future

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 2, 2021 Renovacor, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39271 83-3169838 (State or Other Jurisdiction of Incorporation) (Commission File N

UP TO 8,526,546 SHARES OF COMMON STOCK ISSUABLE UPON THE EXERCISE OF WARRANTS UP TO 12,668,314 SHARES OF COMMON STOCK UP TO 3,500,000 PRIVATE PLACEMENT WARRANTS

Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-260299 Prospectus UP TO 8,526,546 SHARES OF COMMON STOCK ISSUABLE UPON THE EXERCISE OF WARRANTS UP TO 12,668,314 SHARES OF COMMON STOCK UP TO 3,500,000 PRIVATE PLACEMENT WARRANTS This prospectus relates to the issuance by us of up to an aggregate of 8,526,546 shares of our common stock, par value $0.0001 per share (?Common Sto

Renovacor, Inc. P.O. Box 8142 Greenwich, CT 06836 October 29, 2021

CORRESP 1 filename1.htm Renovacor, Inc. P.O. Box 8142 Greenwich, CT 06836 October 29, 2021 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, NE Washington, D.C. 20549 Attn: Michael Davis Re: Renovacor, Inc. Registration Statement on Form S-1 SEC File No. 333-260299 Filed October 15, 2021 Mr. Davis: Pursuant to Rule 461 of Regula

Form S-1

Table of Contents As filed with the Securities and Exchange Commission on October 15, 2021.

Pre-Funded Warrant, dated September 2, 2021.

Exhibit 4.3 THIS SECURITY WAS ORIGINALLY ISSUED IN A TRANSACTION EXEMPT FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND THIS SECURITY MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED IN THE ABSENCE OF SUCH REGISTRATION OR AN APPLICABLE EXEMPTION THEREFROM. THE HOLDER OF THIS SECURITY AGREES FOR THE BENEFIT OF THE COMPANY THAT (A) THIS SECURITY MAY BE OFF

List of Subsidiaries.

Exhibit 21.1 Subsidiaries of Renovacor, Inc. Name of Subsidiary Jurisdiction of Organization Renovacor Holdings, Inc. Delaware

Letter to the Securities and Exchange Commission from Marcum LLP, dated as of October 15, 2021.

Exhibit 16.1 October 15, 2021 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Commissioners: We have read the statements made by Renovacor, Inc. under Item 16.1 of its Form S-1 dated October 15, 2021 regarding the dismissal of Marcum LLP as the independent registered public accounting of Chardan Healthcare Acquisition 2 Corp. effective September 2, 2021. We agree with th

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 30, 2021 Renovacor, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39271 80-0948910 (State or Other Jurisdiction of Incorporation) (Commission File

Forward Looking Statements Certain statements in this Presentation may be considered forward-looking statements within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995, as amended. Forw

September 2021 ????????????????? Exhibit 99.1 Forward Looking Statements Certain statements in this Presentation may be considered forward-looking statements within the meaning of the ?safe harbor? provisions of the United States Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements generally relate to future events or the Company?s future ?nancial or operating p

CHAQ / Chardan Healthcare Acquisition 2 Corp / Broadview Ventures I LLC - SC 13D Activist Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. )* RENOVACOR, INC. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 75989E106 (CUSIP number) Thomas Needham c/o Broadview Ventures

JOINT FILING AGREEMENT

Exhibit 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the foregoing statement on Schedule 13D is filed on behalf of each of the undersigned, and any amendments thereto executed by the undersigned shall be filed on behalf of each of the undersigned without the necessity of filing any additional joint filing agreement. The undersigned acknowledge that each is responsible for the time

Amended and Restated Employment Agreement, by and between the Company and Magdalene Cook, M.D., dated as of May 17, 2021 and effective as of September 2, 2021 (incorporated by reference to Exhibit 10.12 of the Company's Current Report on Form 8-K, filed with the SEC on September 9, 2021).

Exhibit 10.12 EXECUTION COPY AMENDED AND RESTATED EMPLOYMENT AGREEMENT This AMENDED AND RESTATED EMPLOYMENT AGREEMENT (this ?Agreement?) is made, entered into by and between Renovacor, Inc., a Delaware corporation (the ?Company?), and Magdalene Cook (the ?Executive?), dated May 17th, 2021. The Agreement becomes effective upon the closing (the ?Closing?) of the transactions (the ?Merger?) contempla

Employment Agreement, by and between the Company and Mark Semigran, M.D., dated as of May 5, 2021 and effective as of June 2, 2021 (incorporated by reference to Exhibit 10.13 of the Company's Current Report on Form 8-K, filed with the SEC on September 9, 2021).

Exhibit 10.13 Execution Copy EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (this ?Agreement?) is made, entered into by and between Renovacor, Inc., a Delaware corporation (the ?Company?), and Marc Semigran, MD (the ?Executive?), dated May 5, 2021. WHEREAS, the Executive possesses certain experience and expertise that qualifies him to provide the direction and leadership required by the Company; W

Amendment No. 2 to Sponsored Research Agreement, dated as of August 18, 2021 and effective as of July 1, 2021, by and between the Company and Temple University – Of the Commonwealth System of Higher Education (incorporated by reference to Exhibit 10.4 of the Company's Current Report on Form 8-K, filed with the SEC on September 9, 2021).

Exhibit 10.4 [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. Amendment No. 2 to Sponsored Research Agreement This Amendment No. 2 to Sponsored Research Agreement (?Amendment No. 2?) is entered into effective as of July

Changes in Control of Registrant, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Amendment to Registrant's Code of Ethics, or Waiver of a Provision of the Code of Ethics, Change in Shell Company Status, Entry into a Material Definitive Agreement, Material Modification to Rights of Security Holders, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant, Completion of Acquisition or Disposition of Assets

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 2, 2021 Renovacor, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39271 80-0948910 (State or other jurisdiction of incorporation) (Commission File

RENOVACOR, INC. UNAUDITED FINANCIAL STATEMENTS Six Months Ended June 30, 2020 and 2021

Exhibit 99.2 RENOVACOR, INC. UNAUDITED FINANCIAL STATEMENTS Six Months Ended June 30, 2020 and 2021 1 INDEX TO FINANCIAL STATEMENTS (Unaudited) Page Condensed Balance Sheets as of December 31, 2020 and June 30, 2021 F-2 Condensed Statements of Operations for the six months ended June 30, 2020 and 2021 F-3 Condensed Statements of Convertible Preferred Stock and Stockholders? Deficit for the six mon

Certificate of Amendment to the Second Amended and Restated Certificate of Incorporation, dated as of September 2, 2021 (incorporated by reference to Exhibit 3.2 of the Company's Current Report on Form 8-K, filed with the SEC on September 9, 2021).

Exhibit 3.2 STATE OF DELAWARE CERTIFICATE OF AMENDMENT OF CERTIFICATE OF INCORPORATION The corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware does hereby certify: FIRST: That at a meeting of the Board of Directors of Chardan Healthcare Acquisition 2 Corp. resolutions were duly adopted setting forth a proposed amendment of the Certificate

RENOVACOR’S MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Exhibit 99.1 RENOVACOR?S MANAGEMENT?S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS You should read the following discussion and analysis of our financial condition and results of operations together with our financial statements and related notes appearing elsewhere in this Current Report on Form 8-K. Some of the information contained in this discussion and analysis, in

Amendment to Consulting Agreement, by and between the Company and Arthur M. Feldman, M.D., dated as of September 2, 2021 (incorporated by reference to Exhibit 10.17 of the Company's Current Report on Form 8-K, filed with the SEC on September 9, 2021).

Exhibit 10.17 FIRST AMENDMENT TO CONSULTING AGREEMENT THIS FIRST AMENDMENT TO CONSULTING AGREEMENT (this ?First Amendment?), is made and entered into effective as of September 2, 2021 (the ?First Amendment Effective Date?) between Renovacor, Inc. (the ?Company?) and Arthur M. Feldman (the ?Consultant?). Capitalized terms that are used but not defined in this First Amendment shall have the meaning

Second Amended and Restated Certificate of Incorporation, dated as of September 2, 2021 (incorporated by reference to Exhibit 3.1 of the Company's Current Report on Form 8-K, filed with the SEC on September 9, 2021).

Exhibit 3.1 SECOND AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF CHARDAN HEALTHCARE ACQUISITION 2 CORP. Chardan Healthcare Acquisition 2 Corp., a corporation organized and existing under the laws of the State of Delaware (the ?Corporation?), hereby certifies as follows: 1. The name of the Corporation is Chardan Healthcare Acquisition 2 Corp. 2. The Corporation?s Certificate of Incorporation

List of Subsidiaries.

Exhibit 21.1 Subsidiaries of Renovacor, Inc. Name of Subsidiary Jurisdiction of Organization Renovacor Holdings, Inc. Delaware

Letter to the Securities and Exchange Commission from Marcum LLP, dated as of September 9, 2021.

Exhibit 16.1 September 9, 2021 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Commissioners: We have read the statements made by Renovacor, Inc. (formerly known as Chardan Healthcare Acquisition 2 Corp.) under Item 4.01 of its Form 8-K dated September 9, 2021. We agree with the statements concerning our Firm in such Form 8-K; we are not in a position to agree or disagre

Form of Option Award Agreement (incorporated by reference to Exhibit 10.9 of the Company's Current Report on Form 8-K, filed with the SEC on September 9, 2021).

Exhibit 10.9 NOTICE OF GRANT OF [INCENTIVE STOCK OPTION] or [NON-QUALIFIED STOCK OPTION AWARD] RENOVACOR, INC 2021 OMNIBUS INCENTIVE PLAN Renovacor, Inc. (the ?Company?) hereby grants this award of a Non-qualified Stock Option (the ?Award? or ?Option?) as set forth in this Notice of Grant of Non-qualified Stock Option Award (the ?Notice?) to the Grantee designated in this Notice, pursuant to the p

Registration Rights Agreement, dated as of September 2, 2021, by and between the Company and certain of its stockholders (incorporated by reference to Exhibit 10.6 of the Company's Current Report on Form 8-K, filed with the SEC on September 9, 2021).

Exhibit 10.6 Execution Version REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this ?Agreement?), dated as of September 2, 2021 (the ?Effective Date?), is made and entered into by and among Renovacor, Inc., a Delaware corporation (f/k/a Chardan Healthcare Acquisition 2 Corp.) (the ?Company?), and each of the stockholders set forth on the signature pages hereto (each, a ?Stockhold

Employment Agreement, by and between the Company and Matthew Killeen, Ph.D., dated as of August 16, 2021 and effective as of September 1, 2021 (incorporated by reference to Exhibit 10.14 of the Company's Current Report on Form 8-K, filed with the SEC on September 9, 2021).

Exhibit 10.14 Execution Copy EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (this ?Agreement?) is made, entered into by and between Renovacor, Inc., a Delaware corporation (the ?Company?), Matthew Killeen, PhD (the ?Executive?), dated August 16, 2021. WHEREAS, the Executive possesses certain experience and expertise that qualifies him to provide the direction and leadership required by the Company

UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION

Exhibit 99.3 UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION Defined terms included below have the same meaning as terms defined and included elsewhere in the Current Report on Form 8-K (the ?Form 8-K?) filed by the Company with the Securities and Exchange Commission (the ?SEC?) on September 9, 2021. Unless the context otherwise requires, ?Old Renovacor? refers to Renovacor, Inc. prio

Amended and Restated Bylaws (incorporated herein by reference to Exhibit 3.3 to the Company’s Current Report on Form 8-K, as filed with the SEC on September 9, 2021).

Exhibit 3.3 AMENDED AND RESTATED BYLAWS OF RENOVACOR, INC. (the ?Corporation?) ARTICLE I Stockholders Section 1.1. Annual Meeting. The annual meeting of stockholders (any such meeting being referred to in these Bylaws as an ?Annual Meeting?) shall be held at the hour, date and place within or without the United States which is fixed by the Corporation?s Board of Directors (the ?Board of Directors?

Letter Agreement, by and between the Company and Wendy F. DiCicco, dated as of September 3, 2021 (incorporated by reference to Exhibit 10.15 of the Company's Current Report on Form 8-K, filed with the SEC on September 9, 2021).

Exhibit 10.15 September 3, 2021 Dear Wendy, This letter agreement documents the mutual understanding between Renovacor, Inc. (the ?Company? or ?we?) and you regarding a special retention bonus opportunity we are providing to you in connection with the closing of the transactions (the ?Closing?) contemplated by the Agreement and Plan of Merger by and among the Company, CHAQ2 Merger Sub, Inc., and p

Form of Executive Employment Agreement (incorporated by reference to Exhibit 10.11 of the Company's Current Report on Form 8-K, filed with the SEC on September 9, 2021).

Exhibit 10.11 FORM OF EMPLOYMENT AGREEMENT1 This EMPLOYMENT AGREEMENT (this ?Agreement?) is made, entered into by and between Renovacor, Inc., a Delaware corporation (the ?Company?), and [EXECUTIVE NAME] (the ?Executive?), dated [DATE]. WHEREAS, the Executive possesses certain experience and expertise that qualifies him to provide the direction and leadership required by the Company; WHEREAS, the

Renovacor, Inc. 2021 Omnibus Incentive Plan (incorporated by reference to Exhibit 10.8 of the Company's Current Report on Form 8-K, filed with the SEC on September 9, 2021).

Exhibit 10.8 CHARDAN HEALTHCARE ACQUISITION 2 CORP. 2021 OMNIBUS INCENTIVE PLAN Chardan Healthcare Acquisition 2 Corp., a Delaware corporation, sets forth herein the terms of its 2021 Omnibus Incentive Plan, as follows: 1. PURPOSE The Plan is intended to enhance the Company?s and its Affiliates? (as defined herein) ability to attract and retain highly qualified officers, Non-Employee Directors (as

Sponsored Research Agreement, dated as of August 12, 2019, by and between the Company and Temple University – Of the Commonwealth System of Higher Education (incorporated by reference to Exhibit 10.2 of the Company's Current Report on Form 8-K, filed with the SEC on September 9, 2021).

Exhibit 10.2 [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. SPONSORED RESEARCH AGREEMENT THIS AGREEMENT (?Agreement?), effective this 12th day of August, 2019 (?Effective Date?), by and between Temple University ? Of t

Consulting Agreement, by and between the Company and Arthur M. Feldman, M.D., dated as of August 12, 2019 (incorporated by reference to Exhibit 10.16 of the Company's Current Report on Form 8-K, filed with the SEC on September 9, 2021).

Exhibit 10.16 Execution Version CONSULTING AGREEMENT This CONSULTING AGREEMENT (the ?Agreement?) is entered into as of August 12, 2019 between Renovacor, Inc. (the ?Company?) and Arthur M. Feldman (?Consultant?) (each of the foregoing individually a ?Party? and collectively the ?Parties?). WHEREAS, Consultant and the Company have agreed that, effective on the Effective Date, Consultant shall serve

Form of Indemnification Agreement (incorporated by reference to Exhibit 10.10 of the Company's Current Report on Form 8-K, filed with the SEC on September 9, 2021).

Exhibit 10.10 INDEMNIFICATION AGREEMENT THIS INDEMNIFICATION AGREEMENT (the ?Agreement?) is made and entered into effective as of September 2, 2021 between Renovacor, Inc., a Delaware corporation (the ?Company?), and [ ] (?Indemnitee?). WITNESSETH THAT: WHEREAS, highly competent persons have become more reluctant to serve corporations as directors, officers or in other capacities unless they are p

License Agreement, dated as of August 12, 2019, by and between the Company and Temple University – Of the Commonwealth System of Higher Education (incorporated by reference to Exhibit 10.1 of the Company's Current Report on Form 8-K, filed with the SEC on September 9, 2021)

Exhibit 10.1 [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. LICENSE AGREEMENT This License Agreement (?Agreement?) is made effective on the date of the last signature by and between Temple University - Of The Commonwea

Amendment No. 1 to Sponsored Research Agreement, dated as of August 27, 2019, by and between the Company and Temple University – Of the Commonwealth System of Higher Education (incorporated by reference to Exhibit 10.3 of the Company's Current Report on Form 8-K, filed with the SEC on September 9, 2021).

Exhibit 10.3 Amendment No. 1 to Sponsored Research Agreement This Amendment No. 1 (?Amendment No. 1?) is entered into effective August 27, 2019 (?Amendment Date?) and amends the Sponsored Research Agreement effective August 12, 2019 (the ?Agreement?) between Temple University ? Of The Commonwealth System of Higher Education (?University?) and Renovacor Inc., (?Sponsor?). University and Sponsor are

CHAQ / Chardan Healthcare Acquisition 2 Corp / RTW INVESTMENTS, LP Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.

EX-99.25

NOTIFICATION OF THE REMOVAL FROM LISTING AND REGISTRATION OF THE STATED SECURITIES NYSE American LLC hereby notifies the SEC of its intention to remove the entire class of the stated securities from listing and registration on the Exchange at the opening of business on September 14, 2021, pursuant to the provisions of Rule 12d2-2 (a).

CHARDAN HEALTHCARE ACQUISITION 2 CORP. ANNOUNCES STOCKHOLDER APPROVAL OF BUSINESS COMBINATION WITH RENOVACOR, INC.

Exhibit 99.1 CHARDAN HEALTHCARE ACQUISITION 2 CORP. ANNOUNCES STOCKHOLDER APPROVAL OF BUSINESS COMBINATION WITH RENOVACOR, INC. New York, NY, September 1, 2021 ? Chardan Healthcare Acquisition 2 Corp. (NYSE: CHAQ) (?CHAQ?), a special purpose acquisition company sponsored by Chardan Capital Markets (?Chardan?), today announced the results for the proposals considered and voted upon by its stockhold

Regulation FD Disclosure, Financial Statements and Exhibits, Other Events, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 September 1, 2021 Date of Report (Date of earliest event reported) Chardan Healthcare Acquisition 2 Corp. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39271 83-3169838 (State or other jurisdiction of incorporat

Renovacor, Inc. Closes its Business Combination with Chardan Healthcare Acquisition 2 Corp. and Will Begin Trading on the New York Stock Exchange

EX-99.2 3 d73941dex992.htm EX-99.2 Exhibit 99.2 Renovacor, Inc. Closes its Business Combination with Chardan Healthcare Acquisition 2 Corp. and Will Begin Trading on the New York Stock Exchange Common stock and warrants of the combined company, renamed Renovacor, Inc., will commence trading on September 3, 2021 on the NYSE under ticker symbols “RCOR” and “RCOR.WS”, respectively. Gross proceeds fro

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State

SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy Statement ? Definitive Additional Materials ? Soliciting Material under Rule 14a-12 CHARDAN HEALTHCARE ACQUISITION 2 CORP.

SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy Statement ? Definitive Additional Materials ? Soliciting Material under Rule 14a-12 CHARDAN HEALTHCARE ACQUISITION 2 CORP.

SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy Statement ? Definitive Additional Materials ? Soliciting Material under Rule 14a-12 CHARDAN HEALTHCARE ACQUISITION 2 CORP.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 ☐ TRANSITION REPORT PURSUANT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number [001-39271] CHARDAN HEALTHCARE

For Period Ended: June 30, 2021 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q ☐ Transition Report on Form N-SAR For the Transition Period Ended: _____________

NT 10-Q 1 ea145989-nt10qchardan2.htm NT 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER 001-39271 (Check One): ¨ Form 10-K ¨ Form 20-F ¨ Form 11-K x Form 10-Q ¨ Form 10D  ¨ Form N-SAR ¨ Form N-CSR CUSIP NUMBER 15957T107 For Period Ended: June 30, 2021 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20

Sponsor Support Agreement, dated as of March 22, 2021, by and among Chardan Healthcare Acquisition 2 Corp., Chardan Investments 2, LLC, and Renovacor, Inc. (incorporated by reference to Annex E to the Schedule 14A, filed with the SEC on August 5, 2021).

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 29, 2021 CHARDAN HEALTHCARE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 29, 2021 CHARDAN HEALTHCARE ACQUISITION 2 CORP. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39271 83-3169838 (State or other jurisdiction of incorporation

Chardan Healthcare Acquisition 2 Corp. Announces Record Date for Stockholders Eligible to Vote on Merger

Exhibit 99.1 Chardan Healthcare Acquisition 2 Corp. Announces Record Date for Stockholders Eligible to Vote on Merger PHILADELPHIA and NEW YORK, August 3, 2021? Chardan Healthcare Acquisition 2 Corp. (the ?Company?) announced that the close of business on Thursday, August 5, 2021, has been set as the record date for the determination of stockholders eligible to receive the proxy and vote at the sp

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 29, 2021 CHARDAN HEALTHCARE ACQUISITION 2 CORP. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39271 83-3169838 (State or other jurisdiction of incorporation

Joint Filing Statement Pursuant to Rule 13d-1(k)(1)

EX-1 2 ex1.htm Exhibit 1 Joint Filing Statement Pursuant to Rule 13d-1(k)(1) The undersigned hereby consent and agree to the joint filing of Schedule 13G under the Securities Exchange Act of 1934, as amended, with respect to the Common Stock, par value $0.001 per share of Exagen Inc. beneficially owned by them, together with any or all amendments thereto, when and if appropriate. The parties heret

CHAQ / Chardan Healthcare Acquisition 2 Corp / RTW INVESTMENTS, LP Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934* Chardan Healthcare Acquisition 2 Corp.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-

Chardan Healthcare Acquisition 2 Corp. 17 State Street, 21st Floor New York, NY 10004

Chardan Healthcare Acquisition 2 Corp. 17 State Street, 21st Floor New York, NY 10004 July 28, 2021 VIA EDGAR Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Division of Corporation Finance Attention: Dillon Hagius Re: Chardan Healthcare Acquisition 2 Corp. Amendment No. 1 to Preliminary Proxy Statement on Schedule 14A Filed July 14, 2021 File No. 001-39271 Dear Mr. Ha

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of

Chardan Healthcare Acquisition 2 Corp. 17 State Street, 21st Floor New York, NY 10004

Chardan Healthcare Acquisition 2 Corp. 17 State Street, 21st Floor New York, NY 10004 July 14, 2021 VIA EDGAR Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Division of Corporation Finance Attention: Dillon Hagius Re: Chardan Healthcare Acquisition 2 Corp. Preliminary Proxy Statement on Schedule 14A Filed June 4, 2021 File No. 001-39271 Dear Mr. Hagius: This letter se

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

PRER14A 1 d174118dprer14a.htm PRER14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Comm

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of

SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy Statement ? Definitive Additional Materials ? Soliciting Material under Rule 14a-12 CHARDAN HEALTHCARE ACQUISITION 2 CORP.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-

SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy Statement ? Definitive Additional Materials ? Soliciting Material under Rule 14a-12 CHARDAN HEALTHCARE ACQUISITION 2 CORP.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 ☐ TRANSITION REPORT PURSUAN

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39271 CHARDAN HEALTHCARE

Read attached instruction sheet before preparing form. Please Print or Type. Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER 001-39271 (Check One): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K x Form 10-Q ☐ Form 10D ☐ Form N-SAR ☐ Form N-CSR CUSIP NUMBER 15957T107 For Period Ended: March 31, 2021 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transit

JOINT FILING AGREEMENT

EXHIBIT 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on Schedule 13G filed herewith (and any amendments thereto), relating to the common stock of Chardan Healthcare Acquisition 2 Corp., a Delaware corporation, is being filed jointly with the Securities and Exchange Commission pursuant to Rule 13d-1(c) under the Securities Exchange Act of 1934, as amended, on behalf o

April 23, 2021

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G*/ (Rule 13d-102) Chardan Healthcare Acquisition 2 Corp. (Name of Issuer) Common stock, par value $0.0001 per share (Title of Class of Securities) 15957T107 (CUSIP Number) April 23, 2021 Date of Event Which Requires Filing of the Statement Check the appropriate box to designate the rule pursuant to which this Sched

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )*

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Chardan Healthcare Acquisition 2 Corp. (Name of Issuer) Common Stock (Title of Class of Securities) 15957T107 (CUSIP Number) March 23, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to

EXHIBIT 1

EX-1 2 ex-1.htm JOINT ACQUISITION STATEMENT Chardan Healthcare Acquisition 2 Corp. SC 13G EXHIBIT 1 JOINT ACQUISITION STATEMENT PURSUANT TO SECTION 240.13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the u

- CURRENT REPORT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 22, 2021 Date of Report (Date of earliest event reported) Chardan Healthcare Acquisition 2 Corp. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39271 83-3169838 (State or other jurisdiction of incorporation

Form of Stockholder Support Agreement.

Exhibit 10.3 ACQUIROR STOCKHOLDER SUPPORT AGREEMENT This ACQUIROR STOCKHOLDER SUPPORT AGREEMENT (this ?Agreement?), dated as of March 22, 2021 (the ?Effective Date?), is made by and among Chardan Healthcare Acquisition 2 Corp., a Delaware corporation (?Acquiror?), Renovacor, Inc., a Delaware corporation (the ?Company?), and the undersigned holder of shares of common stock of Acquiror, par value $0

Sponsor Support Agreement, dated as of March 22, 2021, by and among Chardan Healthcare Acquisition 2 Corp., Chardan Investments 2, LLC and Renovacor, Inc.

Exhibit 10.2 SPONSOR SUPPORT AGREEMENT This SPONSOR SUPPORT AGREEMENT (this ?Agreement?), dated as of March 22, 2021, is made by and among Chardan Healthcare Acquisition 2 Corp., a Delaware corporation (?Acquiror?), Renovacor, Inc., a Delaware corporation (the ?Company?) and Chardan Investments 2, LLC, a Delaware limited liability company (the ?Sponsor?). Acquiror, the Company and the Sponsor shal

Form of Subscription Agreement.

Exhibit 10.1 SUBSCRIPTION AGREEMENT This SUBSCRIPTION AGREEMENT (this ?Subscription Agreement?) is entered into on March 22, 2021, by and between Chardan Healthcare Acquisition 2 Corp., a Delaware corporation (the ?Company?), and the undersigned subscriber (?Subscriber?). WHEREAS, immediately following the execution and delivery of this Subscription Agreement, the Company will enter into that cert

Investor Presentation dated March 2021.

Exhibit 99.2 March 2021 ????????????????? Confidential This investor presentation (this ?Presentation?) is for informational purposes only to assist interested parties in making their own evaluation with respect to a possible transaction (the ?Business Combination?) involving Renovacor, Inc. (the ?Company?). The information contained herein does not purport to be all - inclusive and none of the Co

March 2021 ––––––––––––––––– Confidential This investor presentation (this “Presentation”) is for informational purposes only to assist interested parties in making their own evaluation with respect to a possible transaction (the “Business Combinatio

Exhibit 99.2 March 2021 ????????????????? Confidential This investor presentation (this ?Presentation?) is for informational purposes only to assist interested parties in making their own evaluation with respect to a possible transaction (the ?Business Combination?) involving Renovacor, Inc. (the ?Company?). The information contained herein does not purport to be all - inclusive and none of the Co

Form of Registration Rights Agreement.

Exhibit 10.4 FORM OF REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this ?Agreement?), dated as of [?], 2021 (the ?Effective Date?), is made and entered into by and among Renovacor, Inc., a Delaware corporation (f/k/a Chardan Healthcare Acquisition 2 Corp.) (the ?Company?), and each of the stockholders set forth on the signature pages hereto (each, a ?Stockholder? collectively,

Press Release, dated March 22, 2021.

Exhibit 99.1 Renovacor, Inc. to Merge with Chardan Healthcare Acquisition 2 Corp. ? Renovacor, Inc. has entered into a definitive merger agreement with Chardan Healthcare Acquisition 2 Corp. (NYSE: CHAQ) ? ? Upon closing, the combined company is expected to receive up to $116 million in proceeds and is expected to be listed on NYSE under the ticker symbol ?RCOR? ? ? The business combination is exp

Renovacor, Inc. to Merge with Chardan Healthcare Acquisition 2 Corp. – Renovacor, Inc. has entered into a definitive merger agreement with Chardan Healthcare Acquisition 2 Corp. (NYSE: CHAQ) – – Upon closing, the combined company is expected to recei

Exhibit 99.1 Renovacor, Inc. to Merge with Chardan Healthcare Acquisition 2 Corp. ? Renovacor, Inc. has entered into a definitive merger agreement with Chardan Healthcare Acquisition 2 Corp. (NYSE: CHAQ) ? ? Upon closing, the combined company is expected to receive up to $116 million in proceeds and is expected to be listed on NYSE under the ticker symbol ?RCOR? ? ? The business combination is exp

Sponsor Support Agreement, dated as of March 22, 2021, by and among Chardan Healthcare Acquisition 2 Corp., Chardan Investments 2, LLC and Renovacor, Inc.

Exhibit 10.2 SPONSOR SUPPORT AGREEMENT This SPONSOR SUPPORT AGREEMENT (this ?Agreement?), dated as of March 22, 2021, is made by and among Chardan Healthcare Acquisition 2 Corp., a Delaware corporation (?Acquiror?), Renovacor, Inc., a Delaware corporation (the ?Company?) and Chardan Investments 2, LLC, a Delaware limited liability company (the ?Sponsor?). Acquiror, the Company and the Sponsor shal

Agreement and Plan of Merger, dated as of March 22, 2021, by and among Chardan Healthcare Acquisition 2 Corp., CHAQ2 Merger Sub, Inc., and Renovacor, Inc.

Exhibit 2.1 AGREEMENT AND PLAN OF MERGER dated as of March 22, 2021 by and among CHARDAN HEALTHCARE ACQUISITION 2 CORP. CHAQ2 MERGER SUB, INC. and RENOVACOR, INC. TABLE OF CONTENTS Page Article I CERTAIN DEFINITIONS 3 1.01 Definitions 3 1.02 Construction 17 Article II THE MERGER; CLOSING 2.01 The Merger 18 2.02 Effects of the Merger 19 2.03 Closing 19 2.04 Organizational Documents of the Company a

Form of Subscription Agreement.

Exhibit 10.1 SUBSCRIPTION AGREEMENT This SUBSCRIPTION AGREEMENT (this ?Subscription Agreement?) is entered into on March 22, 2021, by and between Chardan Healthcare Acquisition 2 Corp., a Delaware corporation (the ?Company?), and the undersigned subscriber (?Subscriber?). WHEREAS, immediately following the execution and delivery of this Subscription Agreement, the Company will enter into that cert

Form of Registration Rights Agreement.

Exhibit 10.4 FORM OF REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this ?Agreement?), dated as of [?], 2021 (the ?Effective Date?), is made and entered into by and among Renovacor, Inc., a Delaware corporation (f/k/a Chardan Healthcare Acquisition 2 Corp.) (the ?Company?), and each of the stockholders set forth on the signature pages hereto (each, a ?Stockholder? collectively,

Form of Stockholder Support Agreement.

Exhibit 10.3 ACQUIROR STOCKHOLDER SUPPORT AGREEMENT This ACQUIROR STOCKHOLDER SUPPORT AGREEMENT (this ?Agreement?), dated as of March 22, 2021 (the ?Effective Date?), is made by and among Chardan Healthcare Acquisition 2 Corp., a Delaware corporation (?Acquiror?), Renovacor, Inc., a Delaware corporation (the ?Company?), and the undersigned holder of shares of common stock of Acquiror, par value $0

Regulation FD Disclosure, Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 22, 2021 Date of Report (Date of earliest event reported) Chardan Healthcare Acquisition 2 Corp. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39271 83-3169838 (State or other jurisdiction of incorporation

Agreement and Plan of Merger, dated as of March 22, 2021, by and among Chardan Healthcare Acquisition 2 Corp., CHAQ2 Merger Sub, Inc., and Renovacor, Inc.

Exhibit 2.1 AGREEMENT AND PLAN OF MERGER dated as of March 22, 2021 by and among CHARDAN HEALTHCARE ACQUISITION 2 CORP. CHAQ2 MERGER SUB, INC. and RENOVACOR, INC. TABLE OF CONTENTS Page Article I CERTAIN DEFINITIONS 3 1.01 Definitions 3 1.02 Construction 17 Article II THE MERGER; CLOSING 2.01 The Merger 18 2.02 Effects of the Merger 19 2.03 Closing 19 2.04 Organizational Documents of the Company a

Form of Compensation Committee Charter

Exhibit 99.2 CHARDAN HEALTHCARE ACQUISITION 2 CORP. COMPENSATION COMMITTEE CHARTER OF THE BOARD OF DIRECTORS Purpose of the Committee The purposes of the Compensation Committee (the ?Committee?) of the Board of Directors (the ?Board?) of Chardan Healthcare Acquisition 2 Corp. (the ?Company?) shall be to oversee the Company?s compensation and employee benefit plans and practices, including its exec

Form of Nominating Committee Charter

Exhibit 99.3 CHARDAN HEALTHCARE ACQUISITION 2 CORP. CHARTER OF NOMINATING AND CORPORATE GOVERNANCE COMMITTEE OF THE BOARD OF DIRECTORS Purpose The Nominating and Corporate Governance Committee (?Committee?) is a committee of the Board of Directors (the ?Board?) of Chardan Healthcare Acquisition 2 Corp. (the ?Company?), established to help ensure that the Board is properly constituted to meet its f

Annual Report - ANNUAL REPORT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 or ? TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-39421 CHARDAN HEALTHCARE ACQUISITION

Form of Audit Committee Charter

Exhibit 99.1 CHARDAN HEALTHCARE ACQUISITION 2 CORP. CHARTER OF THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS Purpose and Policy The primary purpose of the Audit Committee (the ?Committee?) shall be to act on behalf of the Board of Directors (the ?Board?) of Chardan Healthcare Acquisition 2 Corp. (the ?Company?), in fulfilling the Board?s oversight responsibilities with respect to the Company?s cor

Form of Code of Ethics

Exhibit 14 CODE OF CONDUCT AND ETHICS OF CHARDAN HEALTHCARE ACQUISITIONS 2 CORP. Adopted: April 23, 2020 The Board of Directors of Chardan Healthcare Acquisition 2 Corp. (the ?Company?) has adopted this Code of Ethics (this ?Code?) to provide value for our stockholders; and ? To encourage honest and ethical conduct, including fair dealing and the ethical handling of conflicts of interest; ? To pro

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Chardan Healthcare Acquisition 2 Corp (Name of Issuer) Common Stock, par value $0.0001 per share (Title o

SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Chardan Healthcare Acquisition 2 Corp (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 15957T107 (CUSIP Number) December 31, 2020 (Date of Event which Requires Filing of this Statement) Check the appropriate

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G (Rule 13d-102) Under the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G (Rule 13d-102) Under the Securities Exchange Act of 1934 Chardan Healthcare Acquisition 2 Corp. (Name of Issuer) Common Shares (Title of Class of Securities) 15957T107 (CUSIP Number) January 22, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to

Quarterly Report - QUARTERLY REPORT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-39271 Chardan Heal

Quarterly Report - QUARTERLY REPORT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-39271 Chardan Healthcar

CHARDAN HEALTHCARE ACQUISITION 2 CORP. BALANCE SHEET APRIL 28, 2020

Exhibit 99.1 CHARDAN HEALTHCARE ACQUISITION 2 CORP. BALANCE SHEET APRIL 28, 2020 Pro Forma April 28, 2020 Adjustments As Adjusted (unaudited) (unaudited) ASSETS Current assets Cash $ 1,128,077 $ - $ 1,128,077 Prepaid expenses 96,800 - 96,800 Total Current Assets 1,224,877 - 1,224,877 Cash held in Trust Account 85,000,000 1,226,440 86,226,440 Total Assets $ 86,224,877 $ 1,226,440 $ 87,451,317 LIABI

Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 5, 2020 Date of Report (Date of earliest event reported) Chardan Healthcare Acquisition 2 Corp (Exact Name of Registrant as Specified in its Charter) Delaware 001-39271 83-3169838 (State or other jurisdiction of incorporation) (

Quarterly Report - QUARTERLY REPORT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-39271 Chardan Healthca

JOINT FILING AGREEMENT

EXHIBIT 1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any and all amendments thereto) with respect to the common stock, $0.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO §240.13d-2 Chardan Hea

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO ?240.13d-2 Chardan Healthcare Acquisition 2 Corp. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 15957T 107 (CUSIP Number) April 24, 2020 (

CHARDAN HEALTHCARE ACQUISITION 2 CORP. INDEX TO FINANCIAL STATEMENTS

EXHIBIT 99.1 CHARDAN HEALTHCARE ACQUISITION 2 CORP. INDEX TO FINANCIAL STATEMENTS Page Report of Independent Registered Public Accounting Firm F-2 Balance Sheet F-3 Notes to the Balance Sheet F-4 F-1 REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM To the Shareholders and Board of Directors of Chardan Healthcare Acquisition 2 Corp. Opinion on the Financial Statements We have audited the acc

Financial Statements and Exhibits, Other Events - CURRENT REPORT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 April 28, 2020 Date of Report (Date of earliest event reported) Chardan Healthcare Acquisition 2 Corp. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39271 83-3169838 (State or other jurisdiction of incorporation

Stock Escrow Agreement, dated April 23, 2020, among the Registrant, Continental Stock Transfer & Trust Company and the Initial Stockholders.

Exhibit 10.3 STOCK ESCROW AGREEMENT This STOCK ESCROW AGREEMENT, dated as of April 23, 2020 (“Agreement”), by and among CHARDAN HEALTHCARE ACQUISITION 2 CORP., a Delaware corporation (“Company”) and the initial shareholders listed on the signature pages hereto (collectively, the “Initial Shareholders”) and CONTINENTAL STOCK TRANSFER & TRUST COMPANY, a New York corporation (“Escrow Agent”). WHEREAS

Letter Agreements, dated April 23, 2020, among the Registrant and the Company’s officers, directors and Initial Stockholders.

Exhibit 10.1 April 23, 2020 Chardan Healthcare Acquisition 2 Corp. 17 State Street, 21st Floor New York, NY 10004 Chardan Capital Markets, LLC 17 State Street, 21st Floor New York, NY 10004 Re: Initial Public Offering Gentlemen: This letter is being delivered to you in accordance with the Underwriting Agreement (the “Underwriting Agreement”) entered into by and between Chardan Healthcare Acquisiti

Promissory Note, dated April 28, 2020, by and between the Registrant and Chardan Investments 2, LLC

Exhibit 10.5 THIS NOTE HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”). THIS NOTE HAS BEEN ACQUIRED FOR INVESTMENT ONLY AND MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF REGISTRATION OF THE RESALE THEREOF UNDER THE SECURITIES ACT OR AN OPINION OF COUNSEL REASONABLY SATISFACTORY IN FORM, SCOPE AND SUBSTANCE TO THE COMPANY THAT SUCH REGISTRATI

Amended and Restated Certificate of Incorporation.

Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF CHARDAN HEALTHCARE ACQUISITION 2 CORP. Pursuant to Section 245 of the Delaware General Corporation Law Chardan Healthcare Acquisition 2 Corp., a corporation existing under the laws of the State of Delaware (the “Corporation”), by its Chief Executive Officer, hereby certifies as follows: 1. The name of the Corporation is “Chardan Heal

Subscription Agreement, dated April 23, 2020, by and between the Registrant and Chardan Investments 2, LLC

Exhibit 10.7 April 23, 2020 Chardan Healthcare Acquisition 2 Corp. 17 State Street, 21st Floor New York, NY 10004 Ladies and Gentlemen: Chardan Healthcare Acquisition 2 Corp. (the “Company”), a blank check company formed for the purpose of acquiring one or more businesses or entities (a “Business Combination”), intends to register its securities under the Securities Act of 1933, as amended (“Secur

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

United States SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 April 23, 2020 Date of Report (Date of earliest event reported) Chardan Healthcare Acquisition 2 Corp. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39271 83-3169838 (State or other jurisdiction of incorporation

Registration Rights Agreement, dated April 23, 2020, by and between the Registrant and Initial Stockholders.

Exhibit 10.4 REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”) is entered into as of the 23rd day of April, 2020, by and among Chardan Healthcare Acquisition 2 Corp., a Delaware corporation (the “Company”) and the undersigned parties listed under Investor on the signature page hereto (each, an “Investor” and collectively, the “Investors”). WHEREAS, the Investors a

Underwriting Agreement, dated April 23, 2020, by and between the Company and Chardan Capital Markets, LLC.

Exhibit 1.1 8,500,000 Units Chardan Healthcare Acquisition 2 Corp. UNDERWRITING AGREEMENT April 23, 2020 Chardan Capital Markets, LLC 17 State Street, Suite 1600 New York, New York 10004 As Representative of the Underwriters named on Schedule A hereto Ladies and Gentlemen: The undersigned, Chardan Healthcare Acquisition 2 Corp., a Delaware corporation (“Company”), hereby confirms its agreement wit

Investment Management Trust Agreement, dated April 23, 2020, by and between Continental Stock Transfer & Trust Company and the Company.

Exhibit 10.2 INVESTMENT MANAGEMENT TRUST AGREEMENT This Agreement is made as of April 23, 2020 by and between Chardan Healthcare Acquisition 2 Corp. (the “Company”) and Continental Stock Transfer & Trust Company (“Trustee”). WHEREAS, the Company’s registration statement on Form S-1, No. 333-236977 (“Registration Statement”) for its initial public offering of securities (“IPO”) has been declared ef

Indemnity Agreements, dated April 23, 2020, by and among the Registrant and the directors and officers of the Registrant

Exhibit 10.6 FORM OF INDEMNITY AGREEMENT THIS INDEMNITY AGREEMENT (this “Agreement”) is made as of April 23, 2020, by and between Chardan Healthcare Acquisition 2 Corp., a Delaware corporation (the “Company”), and the undersigned (“Indemnitee”). RECITALS WHEREAS, highly competent persons have become more reluctant to serve publicly held corporations as directors, officers or in other capacities un

Warrant Agreement, dated April 23, 2020, by and between Continental Stock Transfer & Trust Company and the Company (incorporated by reference to Exhibit 4.1 to the Registration Statement on Form S-1/A, filed with the SEC on April 29, 2020)

Exhibit 4.1 WARRANT AGREEMENT This Warrant Agreement (“Warrant Agreement”) is made as of April 23, 2020, by and between Chardan Healthcare Acquisition 2 Corp., a Delaware corporation (the “Company”), and Continental Stock Transfer & Trust Company (the “Warrant Agent”). WHEREAS, the Company is engaged in a public offering (the “Public Offering”) of 8,500,000 units (the “Units”) of the Company (and

$85,000,000 CHARDAN HEALTHCARE ACQUISITION 2 CORP. 8,500,000 UNITS

PROSPECTUS Filed Pursuant to Rule 424(b)(4) Registration No. 333-236977 $85,000,000 CHARDAN HEALTHCARE ACQUISITION 2 CORP. 8,500,000 UNITS Chardan Healthcare Acquisition 2 Corp., which we refer to as “we,” “us” or “our company,” is a newly organized blank check company incorporated in Delaware and formed for the purpose of entering into a merger, share exchange, asset acquisition, stock purchase,

Form 8-A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 Chardan Healthcare Acquisition 2 Corp.

- AMENDMENT TO FORM 8-A12B

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-A (Amendment No.

Form of Warrant Agreement between Continental Stock Transfer & Trust Company and the Registrant.

Exhibit 4.4 WARRANT AGREEMENT This Warrant Agreement (?Warrant Agreement?) is made as of , 2020, by and between Chardan Healthcare Acquisition 2 Corp., a Delaware corporation (the ?Company?), and Continental Stock Transfer & Trust Company (the ?Warrant Agent?). WHEREAS, the Company is engaged in a public offering (the ?Public Offering?) of 8,500,000 units (the ?Units?) of the Company (and up to 1,

As filed with the Securities and Exchange Commission on April 17, 2020

As filed with the Securities and Exchange Commission on April 17, 2020 Registration No.

Chardan Healthcare Acquisition 2 Corp. - A Delaware Corporation - CHARDAN HEALTHCARE ACQUISITION 2 CORP. ARTICLE I

Exhibit 3.3 BYLAWS OF Chardan Healthcare Acquisition 2 Corp. - A Delaware Corporation - BY-LAWS OF CHARDAN HEALTHCARE ACQUISITION 2 CORP. ARTICLE I OFFICES SECTION 1. Principal Office. The registered office of the corporation shall be located in such place as may be provided from time to time in the Certificate of Incorporation. SECTION 2. Other Offices. The corporation may also have offices at su

Specimen Unit Certificate.

Exhibit 4.1 NUMBER UNITS U- SEE REVERSE FOR CERTAIN DEFINITIONS CHARDAN HEALTHCARE ACQUISITION 2 CORP. CUSIP UNITS CONSISTING OF ONE SHARE OF COMMON STOCK AND ONE WARRANT, EACH WHOLE WARRANT ENTITLING THE HOLDER TO PURCHASE ONE-HALF OF ONE SHARE OF COMMON STOCK THIS CERTIFIES THAT is the owner of Units. Each Unit (?Unit?) consists of one share of common stock, par value $.0001 per share, of Charda

As filed with the Securities and Exchange Commission on April 15, 2020

As filed with the Securities and Exchange Commission on April 15, 2020 Registration No.

Form of Registration Rights Agreement among the Registrant and the Initial Stockholders and Continental Stock Transfer & Trust Company.

Exhibit 10.4 REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this ?Agreement?) is entered into as of the day of , 2020, by and among Chardan Healthcare Acquisition 2 Corp., a Delaware corporation (the ?Company?) and the undersigned parties listed under Investor on the signature page hereto (each, an ?Investor? and collectively, the ?Investors?). WHEREAS, the Investors and the Com

Form of Subscription Agreement.

Exhibit 10.6 , 2020 Chardan Healthcare Acquisition 2 Corp. 17 State Street, 21st Floor New York, NY 10004 Ladies and Gentlemen: Chardan Healthcare Acquisition 2 Corp. (the ?Company?), a blank check company formed for the purpose of acquiring one or more businesses or entities (a ?Business Combination?), intends to register its securities under the Securities Act of 1933, as amended (?Securities Ac

Specimen Warrant Certificate (incorporated by reference to Exhibit 4.3 of the Registrant’s Registration Statement on Form S-1/A, filed on April 16, 2020).

Exhibit 4.3 SPECIMEN WARRANT CERTIFICATE NUMBER [ ] WARRANTS WA- (THIS WARRANT WILL BE VOID IF NOT EXERCISED PRIOR TO 5:00 P.M. NEW YORK CITY TIME, FIVE YEARS FROM THE CLOSING DATE OF THE COMPANY?S INITIAL BUSINESS COMBINATION) CHARDAN HEALTHCARE ACQUISITION 2 CORP. CUSIP WARRANT THIS WARRANT CERTIFIES THAT, for value received , or registered agents, is the registered holder of a Warrant or Warran

Consent of Isaac Manke.

Exhibit 99.5 CONSENT Chardan Healthcare Acquisition 2 Corp. intends to file a Registration Statement on Form S-1 (together with any amendments or supplements thereto the ?Registration Statement?), registering securities for issuance in its initial public offering. As required by Rule 438 under the Securities Act of 1933, as amended, the undersigned hereby consents to being named in the Registratio

Form of Escrow Agreement between the Registrant, Continental Stock Transfer & Trust Company and the Initial Stockholders.

Exhibit 10.3 STOCK ESCROW AGREEMENT This STOCK ESCROW AGREEMENT, dated as of , 2020 (?Agreement?), by and among CHARDAN HEALTHCARE ACQUISITION 2 CORP., a Delaware corporation (?Company?) and the initial shareholders listed on the signature pages hereto (collectively, the ?Initial Shareholders?) and CONTINENTAL STOCK TRANSFER & TRUST COMPANY, a New York corporation (?Escrow Agent?). WHEREAS, the Co

Consent of Richard Giroux.

Exhibit 99.7 CONSENT Chardan Healthcare Acquisition 2 Corp. intends to file a Registration Statement on Form S-1 (together with any amendments or supplements thereto the ?Registration Statement?), registering securities for issuance in its initial public offering. As required by Rule 438 under the Securities Act of 1933, as amended, the undersigned hereby consents to being named in the Registratio

Form of Letter Agreement among the Registrant, Chardan and the Company’s officers, directors and stockholders.

Exhibit 10.1 , 2020 Chardan Healthcare Acquisition 2 Corp. 17 State Street, 21st Floor New York, NY 10004 Chardan Capital Markets, LLC 17 State Street, 21st Floor New York, NY 10004 Re: Initial Public Offering Gentlemen: This letter is being delivered to you in accordance with the Underwriting Agreement (the ?Underwriting Agreement?) entered into by and between Chardan Healthcare Acquisition 2 Cor

Consent of Michael Rice.

Exhibit 99.6 CONSENT Chardan Healthcare Acquisition 2 Corp. intends to file a Registration Statement on Form S-1 (together with any amendments or supplements thereto the ?Registration Statement?), registering securities for issuance in its initial public offering. As required by Rule 438 under the Securities Act of 1933, as amended, the undersigned hereby consents to being named in the Registratio

Certificate of Incorporation.

Exhibit 3.1 Delaware The First State I, JEFFREY W. BULLOCK, SECRETARY OF STATE OF THE STATE OF DELAWARE, DO HEREBY CERTIFY THE ATTACHED IS A TRUE AND CORRECT COPY OF THE CERTIFICATE OF INCORPORATION OF ?CHARDAN HEALTHCARE ACQUISITION II CORP.?, FILED IN THIS OFFICE ON THE NINETEENTH DAY OF DECEMBER, A.D. 2018, AT 1:55 O?CLOCK P.M. A FILED COPY OF THIS CERTIFICATE HAS BEEN FORWARDED TO THE KENT COU

Form of Underwriting Agreement.

Exhibit 1.1 8,500,000 Units Chardan Healthcare Acquisition 2 Corp. UNDERWRITING AGREEMENT [?], 2020 Chardan Capital Markets, LLC 17 State Street, Suite 1600 New York, New York 10004 As Representative of the Underwriters named on Schedule A hereto Ladies and Gentlemen: The undersigned, Chardan Healthcare Acquisition 2 Corp., a Delaware corporation (?Company?), hereby confirms its agreement with Cha

Form of Investment Management Trust Agreement between Continental Stock Transfer & Trust Company and the Registrant.

Exhibit 10.2 INVESTMENT MANAGEMENT TRUST AGREEMENT This Agreement is made as of , 2020 by and between Chardan Healthcare Acquisition 2 Corp. (the ?Company?) and Continental Stock Transfer & Trust Company (?Trustee?). WHEREAS, the Company?s registration statement on Form S-1, No. 333-236977 (?Registration Statement?) for its initial public offering of securities (?IPO?) has been declared effective

Form of Warrant Agreement between Continental Stock Transfer & Trust Company and the Registrant.

Exhibit 4.4 WARRANT AGREEMENT This Warrant Agreement (?Warrant Agreement?) is made as of , 2020, by and between Chardan Healthcare Acquisition 2 Corp., a Delaware corporation (the ?Company?), and Continental Stock Transfer & Trust Company (the ?Warrant Agent?). WHEREAS, the Company is engaged in a public offering (the ?Public Offering?) of 8,500,000 units (the ?Units?) of the Company (and up to 1,

Specimen Common Stock Certificate.

Exhibit 4.2 NUMBER SHARES C CHARDAN HEALTHCARE ACQUISITION 2 CORP. INCORPORATED UNDER THE LAWS OF THE STATE OF DELAWARE COMMON STOCK SEE REVERSE FOR CERTAIN DEFINITIONS CUSIP This Certifies that is the owner of FULLY PAID AND NON-ASSESSABLE SHARES OF COMMON STOCK OF CHARDAN HEALTHCARE ACQUISITION 2 CORP. transferable on the books of the Company in person or by duly authorized attorney upon surrend

Form of Amended and Restated Certificate of Incorporation.

Exhibit 3.2 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF CHARDAN HEALTHCARE ACQUISITION 2 CORP. Pursuant to Section 245 of the Delaware General Corporation Law Chardan Healthcare Acquisition 2 Corp., a corporation existing under the laws of the State of Delaware (the ?Corporation?), by its Chief Executive Officer, hereby certifies as follows: 1. The name of the Corporation is ?Chardan Heal

Consent of Matthew Rossen.

Exhibit 99.4 CONSENT Chardan Healthcare Acquisition 2 Corp. intends to file a Registration Statement on Form S-1 (together with any amendments or supplements thereto the ?Registration Statement?), registering securities for issuance in its initial public offering. As required by Rule 438 under the Securities Act of 1933, as amended, the undersigned hereby consents to being named in the Registratio

Form of Indemnity Agreement.

Exhibit 10.5 FORM OF INDEMNITY AGREEMENT THIS INDEMNITY AGREEMENT (this ?Agreement?) is made as of , 2020, by and between Chardan Healthcare Acquisition 2 Corp., a Delaware corporation (the ?Company?), and (?Indemnitee?). RECITALS WHEREAS, highly competent persons have become more reluctant to serve publicly held corporations as directors, officers or in other capacities unless they are provided w

Consent of R.A. Session II.

Exhibit 99.8 CONSENT Chardan Healthcare Acquisition 2 Corp. intends to file a Registration Statement on Form S-1 (together with any amendments or supplements thereto the ?Registration Statement?), registering securities for issuance in its initial public offering. As required by Rule 438 under the Securities Act of 1933, as amended, the undersigned hereby consents to being named in the Registratio

As filed with the Securities and Exchange Commission on March 6, 2020

As filed with the Securities and Exchange Commission on March 6, 2020 Registration No.

Promissory Note, dated June 28, 2019, between the Registrant and Chardan Investments 2, LLC (formerly known as Chardan Healthcare Acquisition III Corp.).

Exhibit 10.6 THIS NOTE HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?). THIS NOTE HAS BEEN ACQUIRED FOR INVESTMENT ONLY AND MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF REGISTRATION OF THE RESALE THEREOF UNDER THE SECURITIES ACT OR AN OPINION OF COUNSEL REASONABLY SATISFACTORY IN FORM, SCOPE AND SUBSTANCE TO THE COMPANY THAT SUCH REGISTRATI

Confidentially submitted to the Securities and Exchange Commission on January 15, 2020 This draft registration statement has not been publicly filed with the U.S. Securities and Exchange Commission and all information herein remains strictly confiden

Confidentially submitted to the Securities and Exchange Commission on January 15, 2020 This draft registration statement has not been publicly filed with the U.